Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Product/Service

Phonak Announces FDA Cleared Self-Replacement Option for Lyrictm Hearing Device


Phonak, a leading global provider of life-changing hearing solutions, today announces an FDA cleared self-replacement option for Phonak Lyric, the world's only 100% invisible hearing aid? that provides 24/7 hassle-free hearing? with proven tinnitus relief. With the new clearance, certified Lyric providers in the U.S. can now offer experienced wearers the ability to replace their Lyric devices independently, further enhancing accessibility and reducing in-office visits.

Lyric with self-replacement is a hearing care professional-guided option for patients who would feel comfortable replacing their Lyric hearing aids every other time on their own.

Key benefits of the self-replacement model include:

Phonak Lyric is endorsed by hearing care professionals and has long been recognized for its unmatched invisibility and convenience among wearers. The self-replacement option offers patients the same exceptional benefits as traditional Lyric devices, including 100% invisible hearing, clear natural sound, hassle-free 24/7 hearing, and tinnitus relief day and night. Additionally, the Lyric subscription model ensures patients receive the latest updates at no additional charge.

Self-replacement is optional and not suitable for everyone. Patients interested in incorporating self-replacement into their Lyric hearing experience are encouraged to schedule a consultation with their Lyric provider to discuss candidacy.

For more information about the Phonak Lyric Self-Replacement option, or to find a local Lyric provider, please visit the Phonak website.

References

  1. Leibundgut, M. (2017). Market Research ID #1054, please contact [email protected] if you are interested in more information
  2. Gardner-Branson, G. (2020). Lyric self-replacement: safety, efficacy and precision. Phonak Field Study News. Retrieved from www.phonakpro.com/evidence, accessed January

About Phonak

life is on. Since 1947, Phonak has been dedicated to improving the quality of life for people with hearing loss. Seventy-five years later, our passion for creating life-changing hearing solutions that help people thrive physically, socially, and emotionally remains. By offering the industry's broadest portfolio of hearing solutions, we're committed to creating a world where "life is on" for everyone.

At Phonak, innovation is not limited to products. We work to change the conversations surrounding people with hearing loss. We do this by fighting the stigma of hearing aids and creating an understanding of how hearing is connected to the broader context of healthy living.


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: